Last reviewed · How we verify
Hyperpolarized 129 Xenon
Hyperpolarized 129 Xenon is a Hyperpolarized noble gas contrast agent Small molecule drug developed by Children's Hospital Medical Center, Cincinnati. It is currently FDA-approved for Pulmonary ventilation and gas exchange imaging in patients with chronic obstructive pulmonary disease (COPD), Assessment of lung function in cystic fibrosis, Evaluation of asthma and other obstructive airway diseases. Also known as: HP 129 Xe.
Hyperpolarized 129 xenon is inhaled as a contrast agent for magnetic resonance imaging (MRI) that enhances visualization of lung ventilation and gas exchange.
Hyperpolarized 129 xenon is inhaled as a contrast agent for magnetic resonance imaging (MRI) that enhances visualization of lung ventilation and gas exchange. Used for Pulmonary ventilation and gas exchange imaging in patients with chronic obstructive pulmonary disease (COPD), Assessment of lung function in cystic fibrosis, Evaluation of asthma and other obstructive airway diseases.
At a glance
| Generic name | Hyperpolarized 129 Xenon |
|---|---|
| Also known as | HP 129 Xe |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Drug class | Hyperpolarized noble gas contrast agent |
| Modality | Small molecule |
| Therapeutic area | Pulmonology / Respiratory Imaging |
| Phase | FDA-approved |
Mechanism of action
Xenon-129 is hyperpolarized (aligned nuclear spins) to increase its MRI signal sensitivity by several orders of magnitude, allowing real-time imaging of air distribution in the lungs and measurement of gas diffusion across the alveolar-capillary membrane. This enables functional assessment of pulmonary ventilation and perfusion without ionizing radiation, providing detailed maps of regional lung function.
Approved indications
- Pulmonary ventilation and gas exchange imaging in patients with chronic obstructive pulmonary disease (COPD)
- Assessment of lung function in cystic fibrosis
- Evaluation of asthma and other obstructive airway diseases
Common side effects
- Minimal adverse events reported; generally well-tolerated
Key clinical trials
- Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology (PHASE2, PHASE3)
- 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Xenon MRI and Progressive ILD (PHASE2)
- 129 Xenon Imaging in Patients Treated With Sotatercept (PHASE2)
- Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults (PHASE1, PHASE2)
- Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease (PHASE1, PHASE2)
- Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment
- 129Xe MRI in Pediatric Population With BPD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperpolarized 129 Xenon CI brief — competitive landscape report
- Hyperpolarized 129 Xenon updates RSS · CI watch RSS
- Children's Hospital Medical Center, Cincinnati portfolio CI
Frequently asked questions about Hyperpolarized 129 Xenon
What is Hyperpolarized 129 Xenon?
How does Hyperpolarized 129 Xenon work?
What is Hyperpolarized 129 Xenon used for?
Who makes Hyperpolarized 129 Xenon?
Is Hyperpolarized 129 Xenon also known as anything else?
What drug class is Hyperpolarized 129 Xenon in?
What development phase is Hyperpolarized 129 Xenon in?
What are the side effects of Hyperpolarized 129 Xenon?
Related
- Drug class: All Hyperpolarized noble gas contrast agent drugs
- Manufacturer: Children's Hospital Medical Center, Cincinnati — full pipeline
- Therapeutic area: All drugs in Pulmonology / Respiratory Imaging
- Indication: Drugs for Pulmonary ventilation and gas exchange imaging in patients with chronic obstructive pulmonary disease (COPD)
- Indication: Drugs for Assessment of lung function in cystic fibrosis
- Indication: Drugs for Evaluation of asthma and other obstructive airway diseases
- Also known as: HP 129 Xe
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing